DrugPatentWatch Database Preview

TRINTELLIX Drug Profile

« Back to Dashboard

Which patents cover Trintellix, and what generic alternatives are available?

Trintellix is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and two patent family members in forty-one countries.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vortioxetine hydrobromide profile page.

Summary for TRINTELLIX

International Patents:	202
US Patents:	10
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	108
Clinical Trials:	7
Patent Applications:	64
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TRINTELLIX
Drug Sales Revenues:	Drug sales revenues for TRINTELLIX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRINTELLIX
Prior Art and Litigation Support	Order Prior Art and Litigation support for TRINTELLIX
DailyMed Link:	TRINTELLIX at DailyMed

Generic Entry Opportunity Date for TRINTELLIX

NDA:

204447

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for TRINTELLIX

1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine monohydrobromide

1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl}piperazine

1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine

1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine hydrobromide

1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)PIPERAZINE HYDROCHLRIDE

1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine

1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine

1-[2-(2,4-Dimethylphenylsulfanyl)-phenyl]piperazine

1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-hbr

1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine

1-[2-[(2,4-dimethylphenyl)thio]phenyl]piperazine hydrobromide

1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine

1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine hydrobromide

2796AH

3O2K1S3WQV

4-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide

4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium bromide

4CH-016292

508233-74-7

7034AB

960203-27-4

A3926

AB0165485

AC-27648

AC-28325

AJ-86685

AKOS016008748

AKOS016340374

API0019472

AX8224799

BCP05996

BCP09588

BDBM50400902

Brintellix

Brintellix (TN)

C18H22N2S.BrH

CCG-229998

CHEBI:76015

CHEBI:76016

CHEMBL2104993

CHEMBL2107387

CHEMBL2204360

CS-1471

CS-1472

D10184

D10185

DA-42264

EBD3080710

EX-A2348

FT-0686961

FT-0696676

GG-0052

GTPL7351

HG-0011

HSDB 8250

HY-15414

HY-15414A

KB-81458

KB-81459

KS-0000062Y

Lu AA 21004 hydrobromide

Lu AA 21004 hydrobromide;Lu AA21004 hydrobromide

Lu AA 21004 pound>>LuAA21004 pound>> Lu-AA21004 pound>> Lu AA21004 pound>> AA21004

Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine

Lu AA 21004|||1-[2-[(2,4-dimethylphenyl)thio]phenyl]-piperazine hydrobromide

Lu AA21004

Lu AA21004 (HBr)

Lu-AA-21004

Lu-AA21004-(HBr)

MolPort-023-298-791

MolPort-023-298-793

PIP107

Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-

Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, hydrobromide (1:1)

Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]-

s8021

SB16506

SB16507

SC-53652

SC-95551

SCHEMBL236115

SCHEMBL237653

ST2408515

STL483777

SW219360-1

TKS641KOAY

UNII-3O2K1S3WQV

UNII-TKS641KOAY

VNGRUFUIHGGOOM-UHFFFAOYSA-N

vortioxetina

VORTIOXETINE

Vortioxetine (hydrobromide)

Vortioxetine (Lu AA21004)

Vortioxetine (Lu AA21004) HBr

Vortioxetine (Lu AA21004) hydrobromide

Vortioxetine (USAN)

Vortioxetine [USAN:INN]

Vortioxetine HBr

Vortioxetine hydrobromide

Vortioxetine hydrobromide (JAN/USAN)

Vortioxetine hydrobromide [USAN]

vortioxetine monohydrobromide

Vortioxetine, Lu AA21004

vortioxetinum

W-5909

W-5911

YQNWZWMKLDQSAC-UHFFFAOYSA-N

ZINC34051848

US Patents and Regulatory Information for TRINTELLIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-004	Sep 30, 2013		RX	Yes	Yes
Takeda Pharms Usa	TRINTELLIX	vortioxetine hydrobromide	TABLET;ORAL	204447-003	Sep 30, 2013		DISCN	Yes	No

Paragraph IV (Patent) Challenges for TRINTELLIX

Drugname	Dosage	Strength	RLD	Date
	Tablets	5 mg, 10 mg, 15 mgand 20 mg

International Patents for TRINTELLIX

Country	Patent Number	Estimated Expiration
New Zealand	531556
Japan	2013056933
Eurasian Patent Organization	007537
Slovenia	2219647

Supplementary Protection Certificates for TRINTELLIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1436271	PA2014013	Lithuania		PRODUCT NAME: VORTIOXETINUM; REGISTRATION NO/DATE: EU/1/13/891 20131218
1436271	2014C/036	Belgium		PRODUCT NAME: VORTIOXETINE; AUTHORISATION NUMBER AND DATE: EU/1/13/891 20131220
1436271	300652	Netherlands		PRODUCT NAME: VORTIOXETINE OF EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT ERVAN; REGISTRATION NO/DATE: EU/1/13/891/001-036 20131218
1436271	92397	Luxembourg		PRODUCT NAME: VORTIOXETINE OU UN SEL D ADDITION D ACIDE DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE